ReviewCureus2026
Neuroendocrine Neoplasms of the Gastrointestinal Tract: Morphology, WHO 2022 Grading, and Prognostic Perspectives.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Path beyond the blind end-unravel the imaging spectrum of appendiceal pathologies.Abdominal radiology (New York) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal neuroendocrine neoplasms (GI NENs) represent a heterogeneous group of tumors distinguished by variable morphology, proliferative behavior, and clinical outcomes. Their incidence continues to rise globally, driven by improved detection methods and increased understanding of neuroendocrine biology. This narrative review synthesizes current knowledge on the morphologic, immunohistochemical, and molecular features of GI NENs across anatomic sites, highlighting advances in diagnostic evaluation and the prognostic significance of the WHO 2022 grade. Key diagnostic challenges, including differentiating neuroendocrine tumor grade 3 (NET G3) from neuroendocrine carcinoma (NEC) and accurately assessing mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs), are examined alongside sources of variability such as Ki-67 interpretation and sampling limitations. Emerging prognostic biomarkers, digital pathology applications, and evolving therapeutic strategies, particularly somatostatin analogs, peptide receptor radionuclide therapy, and systemic chemotherapy, are reviewed in the context of precision oncology. Continued integration of molecular profiling, artificial intelligence, and standardized diagnostic approaches promises to refine prognostication and personalize management for patients with GI NENs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.